Company intelligence / Profile preview

IDRx

Boston, Massachusetts, USAidrx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

In the Phase 1/1b StrateGIST 1 trial, IDRX-42 demonstrated a 29% objective response rate across 87 evaluable patients of all KIT mutation subsets, including one complete response and 24 partial responses. For 15 patients with only one prior line of treatment, the objective response rate was 53%, including one complete response and seven partial responses. The drug showed a manageable safety profile and favorable durability[5].

Therapeutic areas: Oncology
Modalities: Small moleculesTyrosine kinase inhibitors (TKIs)
Industry: Biotech

Drug pipeline

1 asset

IDRX-42

Phase 1

Indications: Gastrointestinal stromal tumor (GIST)

Partnerships

Merck KGaABlueprint Medicines

Beyond the preview

Go deeper on IDRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDRx.

Explore the full profile